Amgen (AMGN) FY 2025 Revenue at $36.7 Billion with 9.9% Growth

Amgen (AMGN) reported nearly $36.7 billion in revenue for FY 2025, marking a growth of approximately 9.9% from the previous year. The company's net income reached around $7.7 billion, reflecting a net margin of 21%, up from 12.2% in 2024. Amgen's debt-to-equity ratio stands at roughly 6.3x, indicating a significantly higher level of debt relative to equity, while the current ratio is approximately 1.1x. Revolution Medicines (RVMD), contrastingly, reported zero revenue for FY 2025 and a net loss of about $1.1 billion as it develops cancer therapies. This information helps investors evaluate the financial stability of Biotech companies in their portfolios.